Pesquisar
Autolus Therapeutics PLC
AUTLAdicionar à lista de desejos
1.630USD
+0.040+2.52%
Fechamento 05/15, 16:00（ET）Cotações atrasadas em 15 min
433.83MValor de mercado
PerdaP/L TTM
Mais detalhes de Autolus Therapeutics PLC Empresa
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Informações de Autolus Therapeutics PLC
Código da empresaAUTL
Nome da EmpresaAutolus Therapeutics PLC
Data de listagemJun 22, 2018
CEOItin (Christian Martin)
Número de funcionários647
Tipo de títulosDepository Receipt
Fim do ano fiscalJun 22
EndereçoThe Mediaworks
CidadeLONDON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited Kingdom
Código postalW12 7FP
Telefone442038296230
Sitehttps://www.autolus.com/
Código da empresaAUTL
Data de listagemJun 22, 2018
CEOItin (Christian Martin)
Executivos da empresa Autolus Therapeutics PLC
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Non-Executive Independent Director
Non-Executive Independent Director
10.00K
--
Mr. Brent Rice
Mr. Brent Rice
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
9.40K
--
Dr. Christian Martin Itin, Ph.D.
Dr. Christian Martin Itin, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Martin Pule
Mr. Martin Pule
Founder, Senior Vice President, Chief Scientific Officer
Founder, Senior Vice President, Chief Scientific Officer
--
--
Mr. Christopher Vann
Mr. Christopher Vann
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
--
--
Mr. David Brochu
Mr. David Brochu
Senior Vice President, Chief Technical Officer
Senior Vice President, Chief Technical Officer
--
--
Mr. John Edward Berriman
Mr. John Edward Berriman
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Linda C. Bain
Ms. Linda C. Bain
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. William D. (Bill) Young, Ph.D.
Mr. William D. (Bill) Young, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Elisabeth (Lis) Leiderman, M.D.
Dr. Elisabeth (Lis) Leiderman, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Non-Executive Independent Director
Non-Executive Independent Director
10.00K
--
Mr. Brent Rice
Mr. Brent Rice
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
9.40K
--
Dr. Christian Martin Itin, Ph.D.
Dr. Christian Martin Itin, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Martin Pule
Mr. Martin Pule
Founder, Senior Vice President, Chief Scientific Officer
Founder, Senior Vice President, Chief Scientific Officer
--
--
Mr. Christopher Vann
Mr. Christopher Vann
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
--
--
Mr. David Brochu
Mr. David Brochu
Senior Vice President, Chief Technical Officer
Senior Vice President, Chief Technical Officer
--
--
Detalhamento da receita
Moeda: USDAtualizado em: seg, 6 de abr
Moeda: USDAtualizado em: seg, 6 de abr
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
Os dados relevantes ainda não foram divulgados pela empresa.
Por RegiãoUSD
Nome
Receita
Proporção
United States
1.02M
95.33%
Europe
50.00K
4.67%
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: seg, 20 de abr
Atualizado em: seg, 20 de abr
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BioNTech SE
12.52%
Syncona Investment Management Limited
11.55%
MAK Capital One, LLC
11.27%
Clarus Ventures, LLC
7.70%
Blackstone Inc.
7.70%
Outro
49.26%
Investidores
Investidores
Proporção
BioNTech SE
12.52%
Syncona Investment Management Limited
11.55%
MAK Capital One, LLC
11.27%
Clarus Ventures, LLC
7.70%
Blackstone Inc.
7.70%
Outro
49.26%
Tipos de investidores
Investidores
Proporção
Investment Advisor
23.99%
Hedge Fund
21.10%
Corporation
12.52%
Private Equity
9.43%
Venture Capital
8.01%
Investment Advisor/Hedge Fund
7.75%
Sovereign Wealth Fund
5.64%
Holding Company
5.55%
Research Firm
1.64%
Outro
4.36%
Participação acionária institucional
Atualizado em: qua, 1 de abr
Atualizado em: qua, 1 de abr
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q1
239
209.95M
78.88%
-50.13M
2025Q4
230
194.47M
90.55%
+128.60K
2025Q3
237
202.34M
94.14%
-20.86M
2025Q2
235
223.88M
91.00%
-2.80M
2025Q1
228
230.12M
90.84%
-11.63M
2024Q4
235
229.60M
92.37%
-10.27M
2024Q3
225
234.01M
89.22%
+30.38M
2024Q2
227
202.70M
79.95%
+2.45M
2024Q1
217
200.05M
58.18%
+45.35M
2023Q4
191
140.21M
76.10%
+4.14M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Syncona Investment Management Limited
30.73M
11.55%
+30.73M
--
Sep 30, 2024
MAK Capital One, LLC
30.01M
11.27%
+3.99M
+15.33%
Dec 31, 2025
Clarus Ventures, LLC
20.49M
7.7%
--
--
Sep 30, 2025
Blackstone Inc.
20.49M
7.7%
+20.49M
--
Dec 31, 2025
Armistice Capital LLC
17.50M
6.58%
+1.90M
+12.18%
Dec 31, 2025
Syncona Portfolio Ltd
16.64M
6.25%
--
--
Dec 31, 2025
Qatar Investment Authority
15.00M
5.64%
--
--
Mar 01, 2025
PPF Group N.V.
14.78M
5.55%
+170.00K
+1.16%
Oct 24, 2024
Polygon Management Ltd.
9.50M
3.57%
--
--
Dec 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
Invesco NASDAQ Future Gen 200 ETF
0.56%
Virtus LifeSci Biotech Clinical Trials ETF
0.49%
ALPS Medical Breakthroughs ETF
0.17%
iShares Health Innovation Active ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
iShares Biotechnology ETF
0.02%
SPDR S&P International Small Cap ETF
0.01%
Tema Oncology ETF
0%
Fidelity Fundamental Small-Mid Cap ETF
0%
Ver Mais
Invesco NASDAQ Future Gen 200 ETF
Proporção0.56%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.49%
ALPS Medical Breakthroughs ETF
Proporção0.17%
iShares Health Innovation Active ETF
Proporção0.07%
ProShares Ultra Nasdaq Biotechnology
Proporção0.03%
Invesco Nasdaq Biotechnology ETF
Proporção0.03%
iShares Biotechnology ETF
Proporção0.02%
SPDR S&P International Small Cap ETF
Proporção0.01%
Tema Oncology ETF
Proporção0%
Fidelity Fundamental Small-Mid Cap ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
